Order Article Reprints

Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, et al. Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. Cancers. 2022; 14(3):682. https://doi.org/10.3390/cancers14030682

Schwarze, Julia Katharina, Soizic Garaud, Yanina J. L. Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, and et al. 2022. "Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial" Cancers 14, no. 3: 682. https://doi.org/10.3390/cancers14030682

Schwarze, J. K., Garaud, S., Jansen, Y. J. L., Awada, G., Vandersleyen, V., Tijtgat, J., de Wind, A., Kristanto, P., Seremet, T., Willard-Gallo, K., & Neyns, B. (2022). Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. Cancers, 14(3), 682. https://doi.org/10.3390/cancers14030682